886500-75-0

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Difluoro-4-methoxybenzylamine is used as a synthetic intermediate for the development of various pharmaceuticals. Its unique structure allows for the creation of new drug molecules with specific therapeutic properties, contributing to the advancement of medicine.
Used in Agrochemical Industry:
In the agrochemical sector, 2,3-difluoro-4-methoxybenzylamine is utilized as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides. Its incorporation into these products can enhance their effectiveness in controlling pests and weeds, thereby improving crop yields and food security.
Used in Organic Chemistry Research:
2,3-Difluoro-4-methoxybenzylamine is also employed as a valuable building block in organic chemistry research. Its distinct structure provides opportunities for the exploration of new chemical reactions and the synthesis of novel compounds with potential applications in various fields.

InChI:InChI=1/C8H9F2NO/c1-12-6-3-2-5(4-11)7(9)8(6)10/h2-3H,4,11H2,1H3

Upstream product

• 256417-12-6 4-Methoxy-2,3-difluorobenzonitrile 

Downstream Products

• 1417883-88-5 (2-chloropyrimidin-4-yl)-(2,3-difluoro-4-methoxybenzyl)amine 
• 1417878-93-3 (2,3-difluoro-4-methoxybenzyl)-[2-(5-methoxypyridin-3-yl)pyrimidin-4-yl]amine 
• 1624256-35-4 8-(2,3-difluoro-4-methoxybenzyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-dione 

Relevant academic research and scientific papers

Synthesis and Preliminary Evaluation of 11C-Labeled VU0467485/AZ13713945 and Its Analogues for Imaging Muscarinic Acetylcholine Receptor Subtype 4

Muscarinic acetylcholine receptors (mAChRs) have five distinct subunits (M1–M5) and are involved in the action of the neurotransmitter acetylcholine in the central and peripheral nervous system. Attributed to the promising clinical efficacy of xanomeline, an M1/M4-preferring agonist, in patients of schizophrenia and Alzheimer's disease, M1- or M4-selective mAChR modulators have been developed that target the topographically distinct allosteric sites. Herein we report the synthesis and preliminary evaluation of 11C-labeled positron emission tomography (PET) ligands based on a validated M4R positive allosteric modulator VU0467485 (AZ13713945) to facilitate drug discovery. [11C]VU0467485 and two other ligands were prepared in high radiochemical yields (>30 %, decay-corrected) with high radiochemical purity (>99 %) and high molar activity (>74 GBq μmol?1). In vitro autoradiography studies indicated that these three ligands possess moderate-to-high in vitro specific binding to M4R. Nevertheless, further physiochemical property optimization is necessary to overcome the challenges associated with limited brain permeability.